Topics

Glioblastoma | Prognosis | Blood group 0

Home > Publications > Topics > Glioblastoma > Prognosis > Blood group 0

Wiewrodt R, Kloss M, Jost-Engl J, Troschel FM, Troschel BO, Eich HT, Thomas C, Lemcke L, Stummer W, Wiewrodt D.
Blood group 0 attributes to prolonged progression-free survival, overall survival, and 5-year survival in isocitrate dehydrogenase-wildtype glioblastoma patients with MGMT promoter methylation.
Neurooncol Adv. 2025 Feb 20;7(1):vdaf037. doi: 10.1093/noajnl/vdaf037. PMID: 40351837. Observational study. ˍ